Medically reviewed by Jurairat J. Molina, MD Dermatitis is a group of skin problems related to genes, environment, and ...

and mupirocin ointment. Patch testing with the North American Contact Dermatitis Group (NACDG) standard tray, corticosteroids, vehicles, preservatives, flavorings, corticosteroids, cosmetics ...

SAN CARLOS, CA and FORT WORTH, TX / ACCESSWIRE / January 9, 2025 / CAGE Bio, Inc., a clinical-stage biotechnology company advancing innovative ...

Weaning patients with less-potent topical corticosteroids (10/0 hydrocortisone or desonide cream) or topical calcineurin inhibitors (1% pimecrolimus) may minimize flares (Oppel, Pavicic ...

The US FDA has approved Vtama 1% cream for the topical treatment of atopic dermatitis in adult and pediatric patients aged 2 years and older.

Technoderma Medicines, Inc. ('the Company'), a clinical stage biopharmaceutical company, is pleased to report the Company has completed its Phase 2a clinical trial (NCT06363461) of topical TDM-180935 ...

People with eczema usually experience flare-ups during the winter season. During these periods, symptoms become worse and ...

The FDA approved tapinarof cream 1% (VTAMA; Organon) today to treat patients aged 2 and older with atopic dermatitis. Ahead of its extended target action date of March 12, 2025, the FDA approved ...

Opens in a new tab or window Tapinarof 1% topical cream showed greater efficacy than the control in adults and children as young as age 2 years with atopic dermatitis (AD). The cream also provided ...

CAGE Bio begins phase 2b clinical trial for CGB-500, a breakthrough topical JAK inhibitor for moderate to severe atopic dermatitis: San Carlos, California Saturday, January 11, 20 ...

The U.S. Food and Drug Administration has approved Organon's Vtama (tapinarof) 1% cream for an additional indication -- the topical treatment of atopic dermatitis in adult and pediatric patients ...